800.850.4306
  • Facebook
  • Twitter
  • LinkedIn
  • Facebook
  • Twitter
  • LinkedIn
  • News
  • Media
  • About Us
  • Contact
Biologics by McKesson
  • Patients
  • Providers
  • Biopharma
    • Biologics Rare and Orphan Care
  • Payers
Select Page

PORTRAZZA™ (necitumumab) approved as first-line therapy for metastatic, squamous non-small cell lung cancer, available at Biologics, Inc.

Nov 30, 2015 | Archive

CARY, NC — November 30, 2015 — Biologics, Inc., is pleased to announce that it has been selected by Lilly Oncology as the exclusive specialty pharmacy provider for PORTRAZZA™ (necitumumab). In addition to accessing the drug via specialty distribution, Eli Lilly will...

Recent Posts

  • Video Transcript: Patient Spotlight – Cherie T.
  • Video Transcript: Patient Spotlight – Nicole B.
  • Video Transcript: Patient Spotlight – Karen I.
  • Video Transcript: Patient Spotlight – Larry H.
  • Video Transcript: Patient Spotlight – Erica R.

Archives

  • April 2021
  • March 2021
  • January 2021
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • January 2020
  • August 2019
  • July 2019
  • March 2019
  • December 2018
  • September 2018
  • July 2018
  • June 2018
  • May 2018
  • February 2018
  • January 2018
  • June 2017
  • March 2017
  • February 2016
  • November 2015
  • February 2015
  • December 2014
Biologics by McKesson logo

13000 Weston Parkway
Suite 105
Cary, NC 27513
T. 800.850.4306*

 

Legal
Privacy Notice
Terms of Use

For Patients
Privacy Practices (pdf)
Patient’s Rights (pdf)

Learn more about McKesson

URAC accreditation seal Biologics 2023 ACHC Gold Seal Accreditation ACHC Blue Seal Accreditation in Oncology

 

Home
Patients
Providers
Payers
Biopharma
News
Careers
About Us
Leadership
Contact
Resources

© 2019 McKesson Corporation. All Rights Reserved.